Read How to Taper Psychotropic Medication for your answers and solutions. This book is written by James Harper, bestselling author and medical researcher. Click here
Wellbutrin withdrawal – How to taper Wellbutrin is fully described in How to Taper Psychoactive Medication. The full step by step process in detail. Free assistance is also available if needed.
Wellbutrin Withdrawal Symptoms – What are the symptoms of Wellbutrin withdrawal described as well as how to eliminate Wellbutrin withdrawal symptoms.
Wellbutrin withdrawal – What is the Wellbutrin withdrawal timeline? You will find that in How to Taper Psychoactive Medication. There is a timeline you should follow for a successful Wellbutrin withdrawal.
Wellbutrin withdrawal – Headache is all too common during Wellbutrin withdrawal. Want the solution? It is found in How to Taper Psychoactive Medication.
Wellbutrin withdrawal – Some have anxiety during Wellbutrin withdrawal, and some have fatigue during Wellbutrin withdrawal. How to Taper Psychoactive Medication gives the solutions.
Wellbutrin withdrawal – Nausea during Wellbutrin withdrawal is all too common. It does not need to happen. Read How to Taper Psychoactive Medication for the solution.
Wellbutrin withdrawal – Do you want a list of virtually all Wellbutrin withdrawal side effects? Not only does How to Taper Psychoactive Medication give the Wellbutrin withdrawal side effects but offers solutions.
Wellbutrin withdrawal – Brain zaps caused by Wellbutrin withdrawal can be eliminated quickly. Yes, the solution is in How to Taper Psychotropic Medication.
Wellbutrin ( Bupropion ) Withdrawal
If You Are Already Having Wellbutrin Withdrawal click here
If you are experiencing brain zaps, electrical jolts in the head, click here
Wellbutrin (bupropion) is a medication commonly prescribed for depression and to aid smoking cessation. Like all medications, Wellbutrin can cause withdrawal symptoms when it is stopped abruptly. In this response, we will discuss Wellbutrin withdrawal in greater detail, including symptoms, causes, and management strategies.
Wellbutrin withdrawal can occur when a person abruptly stops taking the medication after a prolonged period of use. Withdrawal symptoms can begin as early as a few hours after the last dose of Wellbutrin and can last for several weeks. Some factors that can increase the likelihood and severity of Wellbutrin withdrawal include a history of seizures or eating disorders, taking high doses of the medication, and taking the medication for an extended period.
Symptoms of Wellbutrin withdrawal can vary in severity and duration. Common symptoms include nausea and vomiting, dizziness or lightheadedness, headache, insomnia, irritability or agitation, anxiety or panic attacks, fatigue or lethargy, and flu-like symptoms, including muscle aches and chills. Some individuals may also experience changes in mood, such as depression or irritability, and in rare cases, suicidal thoughts or behavior.
The onset and duration of withdrawal symptoms can depend on a variety of factors, including the dose and duration of Wellbutrin use, individual differences in metabolism, and other medical conditions. For most people, withdrawal symptoms begin within a few days of stopping Wellbutrin and can last for up to several weeks. In some cases, symptoms may persist for several months.
To manage Wellbutrin withdrawal symptoms, healthcare providers will recommend a gradual tapering schedule to slowly reduce the dosage of the medication. This can help to minimize withdrawal effects and make the transition off the medication smoother. Depending on the individual, tapering schedules can take several weeks or even months. Other management strategies for Wellbutrin withdrawal may include over-the-counter medications to relieve specific symptoms, such as anti-nausea medication or pain relievers. Additionally, lifestyle modifications such as regular exercise, a balanced diet, and stress reduction techniques like mindfulness or meditation can help to alleviate withdrawal symptoms and improve overall well-being.
It’s important to note that while Wellbutrin withdrawal can be uncomfortable, it is generally not life-threatening. However, in rare cases, seizures may occur, especially in individuals with a history of seizures or eating disorders. If you experience seizures or any other concerning symptoms during Wellbutrin withdrawal, it’s important to seek medical attention immediately.
In conclusion, Wellbutrin withdrawal can occur when a person abruptly stops taking the medication after a prolonged period of use. Symptoms of Wellbutrin withdrawal can include nausea and vomiting, dizziness or lightheadedness, headache, insomnia, irritability or agitation, anxiety or panic attacks, fatigue or lethargy, and flu-like symptoms. To manage Wellbutrin withdrawal symptoms, healthcare providers may recommend a gradual tapering schedule to slowly reduce the dosage of the medication. Other management strategies may include over-the-counter medications, lifestyle modifications, and seeking medical attention if symptoms worsen. If you are experiencing Wellbutrin withdrawal symptoms, it’s important to speak with your healthcare provider to discuss management options and ensure your safety and well-being.
1. Hill S et al., “A Case Report of Seizure Induced by Bupropion Nasal Insufflation” Primary Care Companion to the Journal of Clinical Psychiatry [ 2007 ] PMID 17599174 [cited 2023 May 22]
2. Sub Laban T, Saadabadi A. Monoamine Oxidase Inhibitors (MAOI) [Updated 2021 Apr 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539848/ [cited 2023 May 22]
3. Victoria, “Difference Between Zyban and Wellbutrin” DifferenceBetween.net. 2011 Jan 27 [cited 2023 May 22]
4. FDA drug label “Wellbutrin (bupropion hydrochloride Tablets.” [N.D] Ref. No 2978172 [cited 2023 May 22]
5. Wooltorton E, “Health and Drug Alerts: Bupropion (Zyban, Wellbutrin SR) : reports of deaths, seizures, serum sickness.” CMAJ 2002 Jan 8, PMID 11800252 [cited 2023 May 22]
6. Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol. 2015;5(6):357-368. doi:10.1177/2045125315612334 [cited 2023 May 22]
7. Xue C, Zhang X, Cai W. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model. Pharmaceutics. 2017 Dec 21;10(1):1. doi: 10.3390/pharmaceutics10010001. PMID: 29267251; PMCID: PMC5874814. [cited 2023 May 22]
8. Berigan TR, Harazin JS. Bupropion-Associated Withdrawal Symptoms: A Case Report. Prim Care Companion J Clin Psychiatry. 1999;1(2):50-51. doi:10.4088/pcc.v01n0205 [cited 2023 May 22]
9. Berigan TR. Bupropion-Associated Withdrawal Symptoms Revisited: A Case Report. Prim Care Companion J Clin Psychiatry. 2002;4(2):78. doi:10.4088/pcc.v04n0208a [cited 2023 May 22]
10. Hill S, Sikand H, Lee J. A case report of seizure induced by bupropion nasal insufflation. Prim Care Companion J Clin Psychiatry. 2007;9(1):67-69. doi:10.4088/pcc.v09n0114a [cited 2023 May 22]
11. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther. 1980 Oct;215(1):127-34. PMID: 6778989. [cited 2023 May 22]
12. Stassinos GL, Klein-Schwartz W. Bupropion “Abuse” Reported to US Poison Centers. J Addict Med. 2016 Sep-Oct;10(5):357-62. doi: 10.1097/ADM.0000000000000249. PMID: 27504927.[cited 2023 May 22]
13. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol. 2008 May;22(3):330-2. doi: 10.1177/0269881107081550. Erratum in: J Psychopharmacol. 2009 Nov;23(8):1006. PMID: 18515448. [cited 2023 May 22]
14. Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997;58 Suppl 7:11-5; discussion 16. PMID: 9219488. [cited 2023 May 22]
15. Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106-113. doi:10.4088/pcc.v07n0305 [cited 2023 May 22]
16. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166. doi:10.4088/pcc.v06n0403 [cited 2023 May 22]
17. Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol. 2015;5(6):357-368. doi:10.1177/2045125315612334 [cited 2023 May 22]
18. Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. PMID: 30016772. [cited 2023 May 22]
19. Huecker MR, Smiley A, Saadabadi A. Bupropion. [Updated 2023 Apr 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470212/ [cited 2023 July 14]
20. Strike M, Hatcher S. Bupropion injection resulting in tissue necrosis and psychosis: previously undocumented complications of intravenous bupropion use disorder. J Addict Med. 2015 May-Jun;9(3):246-50. doi: 10.1097/ADM.0000000000000114. PMID: 25822212. [cited 2023 May 22]
21. Munoli RN, Kongasseri S, Praharaj SK, Sharma PS. Bupropion precipitating acute psychosis: a case report. Am J Ther. 2014 Mar-Apr;21(2):e45-7. doi: 10.1097/MJT.0b013e31823581c8. PMID: 23698185. [cited 2023 May 22]
22. NIDA. Impacts of Drugs on Neurotransmission. National Institute on Drug Abuse website. March 9, 2017 [cited 2023 May 22]
23. Barry JD, Wills BK. Neurotoxic emergencies. Psychiatr Clin North Am. 2013 Jun;36(2):219-44. doi: 10.1016/j.psc.2013.02.003. Epub 2013 Apr 11. PMID: 23688689. [cited 2023 May 22]
24. Orisakwe OE. The role of lead and cadmium in psychiatry. N Am J Med Sci. 2014;6(8):370-376. doi:10.4103/1947-2714.139283 [cited 2023 May 22]
25. Rare Diseases Govt. Fact Sheet, “Heavy Metal Poisoning.” April 27, 2017[cited 2023 May 22]
26. Lissemore, J.I., Sookman, D., Gravel, P. et al. Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline. Transl Psychiatry 8, 82 (2018). [cited 2023 May 22]
27. Penckofer S, Kouba J, Byrn M, Estwing Ferrans C. Vitamin D and depression: where is all the sunshine?. Issues Ment Health Nurs. 2010;31(6):385-393. doi:10.3109/01612840903437657.[cited 2023 May 22]
28. Weir, K, “The Exercise Effect.” American Psychological Association Vol 42, No. 11 [cited 2023 May 22]
29. Understanding nutrition, depression and mental illnesses Indian J Psychiatry. 2008 Apr-Jun; 50(2): 77–82. T. S. Sathyanarayana Rao, M. R. Asha, B. N. Ramesh, and K. S. Jagannatha Rao. [cited 2023 May 22]
30. Hage MP, Azar ST. The Link between Thyroid Function and Depression. J Thyroid Res. 2012;2012:590648. doi:10.1155/2012/590648. [cited 2023 May 22]
31. Schifano F, Chiappini S, Corkery JM, Guirguis A. Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sci. 2018 Apr 22;8(4):73. doi: 10.3390/brainsci8040073. PMID: 29690558; PMCID: PMC5924409. [cited 2023 May 22]
32. DOJ “GlaxoSmithKlein to Plead Guilty and to pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data, Largest Health Fraud Settlement in US History” [published online] [cited 2023 May 22]
33. Stall N, Godwin J, Juurlink D. Bupropion abuse and overdose. CMAJ. 2014;186(13):1015. doi:10.1503/cmaj.131534 [cited 2023 May 22]
34. van Praag HM. Serotonin precursors in the treatment of depression. Adv Biochem Psychopharmacol. 1982;34:259-86. PMID: 6753514. [cited 2023 May 22]
35. Zagorski N, American Psychiatric Assn News FDA Approves Rapid-Acting Oral Antidepressant [published 24 Oct 2022 online] [cited 2023 May 22]
36. FDA label Auvellty (extromethorphan hydrobromide and bupropion HCL) extended-release tablets for oral use [cited 2023 May 22]
37. CDC Data Brief #347 Prescription Drug Use Among Adults Aged 40-79 in the US and Canada [published August 2019] [cited 2023 Aug 8]
38. Gadde KM, Parker CB, Maner LG, Wagner HR 2nd, Logue EJ, Drezner MK, Krishnan KR. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001 Sep;9(9):544-51. doi: 10.1038/oby.2001.71. PMID: 11557835. [cited 2023 Aug 8]
39. Bystritsky RJ. Cellulitis. Infect Dis Clin North Am. 2021 Mar;35(1):49-60. doi: 10.1016/j.idc.2020.10.002. PMID: 33494874. [cited 2023 Aug 8]
40. Khalid N, Azimpouran M. Necrosis. [Updated 2023 Mar 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557627/ [cited 2023 Aug 8]